See more : Rajeshwari Cans Limited (RCAN.BO) Income Statement Analysis – Financial Results
Complete financial analysis of AVROBIO, Inc. (AVRO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of AVROBIO, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Korporacja KGL S.A. (KGL.WA) Income Statement Analysis – Financial Results
- Glassbox Ltd (GLBX.TA) Income Statement Analysis – Financial Results
- Infund Holding Co., Ltd. (002141.SZ) Income Statement Analysis – Financial Results
- G City Ltd (GCT.TA) Income Statement Analysis – Financial Results
- cbdMD, Inc. (YCBD-PA) Income Statement Analysis – Financial Results
AVROBIO, Inc. (AVRO)
About AVROBIO, Inc.
AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the target disease. The company's product includes AVR-RD-01, a gene therapy for the treatment of Fabry disease. It is also developing AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of type 1 Gaucher disease; AVR-RD-03, for the treatment of Pompe disease; AVR-RD-04 for the treatment of cystinosis; AVR-RD-05 for the treatment of Hunter syndrome; and AVR-RD-06 that is in preclinical stage for the treatment of Gaucher disease type 3. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 617.00K | 4.17M | 1.40M | 1.21M | 850.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit | -617.00K | -4.17M | -1.40M | -1.21M | -850.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 47.08M | 72.19M | 83.11M | 87.24M | 54.97M | 35.10M | 15.19M | 2.66M |
| General & Administrative | 22.69M | 33.25M | 35.73M | 32.99M | 20.84M | 11.15M | 3.20M | 1.96M |
| Selling & Marketing | 23.94M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 23.97M | 33.25M | 35.73M | 32.99M | 20.84M | 11.15M | 3.20M | 1.96M |
| Other Expenses | 0.00 | -456.00K | -285.00K | 516.00K | 2.84M | -118.00K | -19.00K | -6.00K |
| Operating Expenses | 71.05M | 105.43M | 118.84M | 120.23M | 75.81M | 46.24M | 18.39M | 4.63M |
| Cost & Expenses | 71.67M | 105.43M | 118.84M | 120.23M | 75.81M | 46.24M | 18.39M | 4.63M |
| Interest Income | 2.42M | 299.00 | 0.00 | 719.00K | 2.93M | 1.73M | 57.00K | 6.00K |
| Interest Expense | 2.42M | 299.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 617.00K | 1.44M | 1.40M | 1.21M | 850.00K | 380.00K | 45.00K | 39.00K |
| EBITDA | -71.05M | -105.43M | -118.84M | -120.23M | -75.81M | -46.24M | -18.04M | -4.59M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -71.67M | -105.43M | -118.84M | -120.23M | -75.81M | -46.24M | -18.39M | -4.63M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 2.34M | -456.00K | -285.00K | 516.00K | 2.84M | -118.00K | -262.00K | -39.00K |
| Income Before Tax | 12.53M | -105.89M | -119.13M | -119.71M | -72.97M | -46.36M | -18.65M | -4.66M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 377.00K | 157.00K | -1.40M | -1.21M | -850.00K | -118.00K | 243.00K | -6.00K |
| Net Income | 12.16M | -106.05M | -117.73M | -118.51M | -72.12M | -46.36M | -18.65M | -4.66M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | 0.27 | -2.42 | -2.75 | -3.27 | -2.63 | -3.45 | -1.15 | -0.67 |
| EPS Diluted | 0.27 | -2.42 | -2.75 | -3.27 | -2.63 | -3.45 | -1.15 | -0.67 |
| Weighted Avg Shares Out | 44.33M | 43.74M | 42.85M | 36.21M | 27.43M | 13.44M | 16.19M | 6.92M |
| Weighted Avg Shares Out (Dil) | 44.57M | 43.74M | 42.85M | 36.21M | 27.43M | 13.44M | 16.19M | 6.92M |
Protalix Could Claim Substantial Global Market Share In Fabry Disease (NYSEMKT:PLX)
AVROBIO Receives Orphan Drug Designation from the European Medicines Agency for AVR-RD-02, an Investigational Gene Therapy for Gaucher Disease
AVROBIO (AVRO) Presents At 18th Annual Global Healthcare Virtual Conference - Slideshow
AVROBIO (AVRO) Investor Presentation - Slideshow
Restaurant chain Chilango sold in deal that safeguards 130 jobs
AVROBIO (AVRO) Presents At 2020 Wedbush PacGrow Healthcare Conference - Slideshow
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Magenta Therapeutics Reports Recent Business Highlights and Second Quarter Financial Results
Head-To-Head Analysis: Avrobio (NASDAQ:AVRO) and Cellectis (NASDAQ:CLLS)
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Source: https://incomestatements.info
Category: Stock Reports